"We are certainly following the 'Make In India' practices. There are many domestic manufacturers that are capable of supplying all of that drugs that are not of the exempt list.
"And therefore no patient in India is going to suffer anymore...Or have to pay any more for the price which they are paying right now because the domestic industry is very much capable of supplying all of those drugs at very good prices," Sinha told reporters on the sidelines of India Digital Summit.
Medicines to treat kidney stones, cancer chemotherapy and radiotherapy, life-threatening heart rhythm disorders, bone diseases, diabetes, Parkinson's disease, antibiotic to treat infections will now attract customs duty.
Besides, interacting with reporters, Sinha said India is now getting big on its technology intervention.
Also Read
"If you don't give (it at 20 per cent price), then whatever kind of market you have in India, it won't sell, so you will have to follow the 80:20 rule," he added.
On the start-up initiative, he said the government wants to cover all such genuine ventures and provide them guidance.
He said the government is on a reform path to change India and a lot of efforts are underway to boost infrastructure.
He said the government has taken a very broad and sweeping transformation for country's infrastructure sector.